Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2000-1-24
pubmed:abstractText
1. The antagonist activity of a series of diinosine polyphosphates (IpnI, where n=3, 4, 5) was assessed against ATP-activated inward currents at rat P2X(1-4) receptors expressed in Xenopus oocytes and studied under voltage-clamp conditions. 2. Diinosine polyphosphates were prepared by the enzymatic degradation of their corresponding diadenosine polyphosphates (e.g., Ap5A into Ip5I) using 5'-adenylic deaminase, and purified using reverse-phase chromatography. 3. Against ATP-responses at rP2X1 receptors, the potency order for antagonism was (pIC50): Ip5I (8.5)>Ip4I (6.3)>Ip3I (>4.5). Ip5I (10-100 nM) caused a concentration-dependent rightwards displacement of the ATP concentration-response curve without reducing the maximum ATP effect. However, the Schild plot was non-linear which indicated Ip5I is not a competitive antagonist. Blockade by micromolar concentrations of Ip5I was not surmountable. Ip4I also behaved as a non-surmountable antagonist. 4. Against ATP-responses at rP2X3 receptors, the potency order for antagonism was (pIC50): Ip4I (6. 0)>Ip5I (5.6)>Ip3I (>4.5). Blockade by Ip4I (pA2, 6.75) and Ip5I (pA2, 6.27) was surmountable at micromolar concentrations. 5. Diinosine polyphosphates failed to inhibit ATP-responses at rP2X2 receptors, whereas agonist responses at rP2X4 were reversibly potentiated by Ip4I and Ip5I. None of the parent diadenosine polyphosphates behave as antagonists at rP2X1 - 4 receptors. 6. Thus, Ip5I acted as a potent and relatively-selective antagonist at the rP2X1 receptor. This dinucleotide pentaphosphate represents a high-affinity antagonist for the P2X1 receptor, at which it acts in a competitive manner at low (</=100 nM) concentrations but has more complex actions at higher (>100 nM) concentrations.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-10037762, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-10082196, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-10082274, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-10188989, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-10510462, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-7498461, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-7544432, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-7827111, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-7843268, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-8392753, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-8639881, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-8730726, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-8786426, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-8808682, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-8922753, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-9203633, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-9314047, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-9606184, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-9614197, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-9630357, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-9632352, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-9658186, http://linkedlifedata.com/resource/pubmed/commentcorrection/10556935-9755289
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0007-1188
pubmed:author
pubmed:issnType
Print
pubmed:volume
128
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
981-8
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
1999
pubmed:articleTitle
Diinosine pentaphosphate (IP5I) is a potent antagonist at recombinant rat P2X1 receptors.
pubmed:affiliation
Autonomic Neuroscience Institute, Royal Free & University College Medical School, Royal Free Campus, Rowland Hill Street, Hampstead, London NW3 2PF, UK. b.king@ucl.ac.uk
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't